Overview

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Status:
Terminated

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Facet Biotech

Collaborator:

PDL BioPharma, Inc.

Treatments:

Visilizumab